# Loncastuximab Tesirine in WM

> **NCT05190705** · PHASE2 · RECRUITING · sponsor: **Shayna Sarosiek, MD** · enrollment: 36 (estimated)

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Loncastuximab Tesirine
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05190705
- **Lead sponsor:** Shayna Sarosiek, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-17
- **Primary completion:** 2026-05-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05190705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05190705, "Loncastuximab Tesirine in WM". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05190705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*